Universal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH cut its stake in Ultragenyx by 84.6% in Q4, selling 77,300 shares and leaving a 14,094-share position valued at about $323,000.
• Q1 results disappointed: Ultragenyx reported EPS of -$1.84 (miss vs. -$1.50 est) and revenue of $136M (vs. $158M est), though product sales (Crysvita $93M, Dojolvi $18M) and FY-2026 revenue guidance of $730–$760M offer some commercial support.
• Market sentiment is mixed: Institutional ownership is high (≈97.7%) with large stake increases from firms like Jacobs Levy and Aberdeen, while notable insider selling (~111,178 shares in the past 90 days) and analyst downgrades increase near-term volatility risk.

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 84.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,094 shares of the biopharmaceutical company's stock after selling 77,300 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH's holdings in Ultragenyx Pharmaceutical were worth $323,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. raised its position in shares of Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock worth $65,205,000 after acquiring an additional 1,864,164 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Ultragenyx Pharmaceutical by 3.9% in the third quarter. Wellington Management Group LLP now owns 1,945,129 shares of the biopharmaceutical company's stock valued at $58,509,000 after acquiring an additional 73,309 shares during the last quarter. Aberdeen Group plc increased its position in Ultragenyx Pharmaceutical by 51.0% in the fourth quarter. Aberdeen Group plc now owns 1,469,951 shares of the biopharmaceutical company's stock worth $33,809,000 after purchasing an additional 496,295 shares during the period. Alliancebernstein L.P. raised its holdings in Ultragenyx Pharmaceutical by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 1,255,203 shares of the biopharmaceutical company's stock worth $45,639,000 after purchasing an additional 7,823 shares during the last quarter. Finally, GW&K Investment Management LLC raised its holdings in Ultragenyx Pharmaceutical by 139.0% during the 3rd quarter. GW&K Investment Management LLC now owns 1,150,169 shares of the biopharmaceutical company's stock worth $34,597,000 after purchasing an additional 668,881 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Crysvita and Dojolvi product sales provide commercial ballast — Q1 product revenues included Crysvita $93M and Dojolvi $18M, showing underlying commercial traction even as total revenue declined. GlobeNewswire: Q1 Results
• Positive Sentiment: Some analysts remain bullish — a recent published price target of $61.18 signals continued upside expectations from parts of the street, which can support buying interest over the medium term. Analyst Price Target
• Neutral Sentiment: FY-2026 revenue guidance given as $730M–$760M (consensus ~$747M) — the range straddles Street expectations, so the top-line outlook is roughly in line with consensus but leaves EPS guidance unclear in public notes. This tempers but does not resolve near-term earnings concerns. Guidance in Press Release
• Neutral Sentiment: Large institutional holdings and recent stake increases from firms like Vanguard and State Street indicate continued institutional interest that may stabilize trading. MarketBeat: Institutional Holdings
• Negative Sentiment: Q1 EPS missed materially: reported loss per share $1.84 vs. consensus ≈ $1.50–$1.55; revenue fell ~2.2% YoY to $136M, underscoring near-term profitability and growth concerns. These misses are the primary negative driver. Zacks: Q1 Loss, Miss
• Negative Sentiment: Insider selling by the CFO (multiple recent sales, latest ~4,683 shares) may be viewed negatively by some investors as a signal of reduced insider conviction or portfolio diversification. SEC Filing: Insider Sale
• Negative Sentiment: Broader sell-side repositioning (e.g., past Goldman downgrade and mixed analyst actions) increases short-term volatility risk as investors digest the earnings gap and guidance nuance. MarketBeat: Analyst Notes

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Truist Financial raised shares of Ultragenyx Pharmaceutical to a "strong-buy" rating in a research note on Wednesday, March 25th. The Goldman Sachs Group downgraded shares of Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $61.00 to $25.00 in a research note on Tuesday, March 24th. Wedbush reaffirmed a "neutral" rating and issued a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Weiss Ratings lowered shares of Ultragenyx Pharmaceutical from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, April 24th. Finally, Canaccord Genuity Group dropped their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a "buy" rating for the company in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $60.76.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $25.01 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.29 and a 1 year high of $42.37. The business has a 50-day moving average of $22.55 and a two-hundred day moving average of $26.90. The company has a market capitalization of $2.46 billion, a P/E ratio of -4.28 and a beta of 0.39.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.50) by ($0.34). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.38 million. During the same quarter last year, the firm earned ($1.57) EPS. The company's revenue for the quarter was down 2.2% on a year-over-year basis. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.49 EPS for the current fiscal year.

Insider Activity

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 8,135 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president directly owned 76,346 shares in the company, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Eric Crombez sold 7,029 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $160,261.20. Following the completion of the transaction, the executive vice president owned 76,301 shares of the company's stock, valued at $1,739,662.80. This trade represents a 8.44% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 111,178 shares of company stock worth $2,534,628. Corporate insiders own 5.20% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.